Dual-Function Antibody PD-1/CTLA-4 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is Ruijin Hospital. The most-studied condition is Pancreatic Adenocarcinoma Locally Advanced.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
NCT07306273 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Locally Advanced
|
Phase 2 | Recruiting | Ruijin Hospital | China |
|
Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
NCT07306286 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Locally Advanced
|
Phase 2 | Recruiting | Ruijin Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ruijin Hospital | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Dual-Function Antibody PD-1/CTLA-4 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Ruijin Hospital. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dual-Function Antibody PD-1/CTLA-4 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dual-Function Antibody PD-1/CTLA-4 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dual-Function Antibody PD-1/CTLA-4 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.